Free Newsletter
ALSO NOTED: Federal Vioxx trial starts; Schering launches mid-stage trials; Biovail marketing Glumetza; and much more...
> The first federal trial involving Vioxx began today in Houston. The widow of a 53-year-old man says the drug was the cause of her husband's death, but Merck maintains that the husband died from heart disease. The case was moved from New Orleans to Houston after Hurricane Katrina hit. Report
> Germany's Schering has started three Phase II trials to test the safety and efficacy of ZK-EPO for several types of cancer. Report
> Biovail has launched its diabetes drug Glumetza in Canada. Release
> Mylan has received approval for its generic version of Aventis Pharmaceuticals' Amaryl Tablets. Release
And Finally… Researchers are studying a possible link between cancer and stress. Article
More stories about Generics Mylan Laboratories Diabetes Bayer Schering FDA approval Merck Phase II Vioxx heart disease Biovail






SHARE
WITH: